To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Skin Cancer

Featured Content
Ryan McDonald
The Food and Drug Administration has approved Tecentriq in combination with Cotellic and Zelboraf for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.
Jessica Skarzynski
Research in the melanoma space is finding itself facing complex challenges in implementing CAR-T cell therapy, but according to one expert these challenges are not insurmountable.
Kristie L. Kahl
“You have to speak up. What you don’t say is the most predictive of the care you don’t get.”
By Beth Fand Incollingo and Kristie L. Kahl
Patients can pick from a growing array of treatments, from same-day- results surgery to game-changing immunotherapy, to fight the most common type of cancer.
Ryan McDonald
The Food and Drug Administration approved Keytruda to treat patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be treated with surgery or radiation.
Jessica Skarzynski
“The relapse-free survival curves for both treatment arms appear to be reaching a plateau, which is a good sign if we are talking about cure,” said lead study author Dr. Axel Hauschild.
Key opinion leaders close the discussion by considering the future of cutaneous squamous cell carcinoma (CSCC) and promising emerging regimens.
Experts in skin-care management discuss the role of the multidisciplinary team to provide patients with the best treatment strategy.
A discussion of the possibility of managing organ transplant populations with immunotherapy.

Sign In

Not a member? Sign up now!
Continue without login